Related Experiment Video

Updated: Jul 4, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity

Anja Krippner-Heidenreich1, Ingo Grunwald, Gudrun Zimmermann

  • 1University Stuttgart, Institute of Cell Biology and Immunology, Stuttgart, Germany.

Journal of Immunology (Baltimore, Md. : 1950)
|June 5, 2008
PubMed

Insights

Researchers developed a stable single-chain tumor necrosis factor (TNF) molecule. This engineered TNF shows reduced toxicity and enhanced anti-tumor effects, offering a promising therapeutic approach.

Area of Science:

  • Biotechnology
  • Immunology
  • Cancer Therapeutics

Background:

  • Tumor necrosis factor (TNF) is a cytokine with significant antitumoral potential.
  • Clinical application of TNF is hindered by systemic toxicity and ligand instability.
  • Current strategies involve TNF-based fusion proteins to improve targeting.

Purpose of the Study:

  • To engineer a more stable and less toxic variant of TNF.
  • To assess the in vitro and in vivo efficacy of the engineered TNF.
  • To explore novel approaches for TNF-based cancer therapies.

Main Methods:

  • Construction of a single-chain TNF (scTNF) molecule by fusing three TNF monomers with peptide linkers.
  • Evaluation of scTNF stability in vitro and in vivo.
  • Assessment of antitumoral activity and systemic toxicity in mouse models.

Main Results:

  • Single-chain TNF demonstrated increased stability compared to wild-type TNF.
  • scTNF exhibited reduced systemic toxicity in preclinical models.
  • Slightly enhanced antitumoral activity was observed with scTNF in mouse models.

Conclusions:

  • Single-chain variants represent a novel strategy to enhance the functional activity of TNF-based therapeutics.
  • Engineered scTNF offers improved stability and safety profile for potential cancer treatment.
  • This approach holds promise for developing more effective TNF family ligand-based therapies.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...